Replimune Group shares fall 76.96% premarket after FDA rejects RP1 approval for advanced melanoma.
ByAinvest Wire
Tuesday, Jul 22, 2025 7:58 am ET1min read
REPL--
Replimune Group, Inc. plummeted 76.96% in premarket trading, following the FDA's rejection of its Biologics License Application for RP1 in combination with nivolumab for advanced melanoma treatment. The FDA issued a Complete Response Letter, citing inadequate clinical trial evidence, which led to a significant decline in the stock price.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet